If Hck, Fgr or other myeloid Src-family members are involved in A-419259 efficacy in Flt3-ITD+ AML, then mutations in their drug-binding pockets would be anticipated to confer resistance to A-419259 in AML cells. The gene discussed is SRC; the disease is acute myeloid leukemia.